Therapies combining circ-CDYL interference and traditional enzyme inhibitors targeting phosphoinositide 3-kinase (PI3K) and hypoxia-inducible factor asparagine hydroxylase (HIF1AN) effectively inhibit tumor growth in HCC. The gene discussed is CDYL; the disease is hepatocellular carcinoma.